AbbVie Inc.
Methods of treatment of diseases in which IL-13 activity is detrimental using anti-IL-13 antibodies

Abstract:

The present invention is directed to methods for treating diseases in which IL-13 activity is detrimental, including eosinophilic esophagitis (EoE) and asthma, by administering to a subject in need of such treatment, a composition containing an inter leukin-13 (IL-13) antibody, or an antigen binding fragment, thereof.